Back to Trades
Total Value
$0
Filing Date
Aug 15, 2025
2 transactions
Trade Summary
On Jul 25, 2025, Wang Jonathan Jian, Insider, reported $0 of ImageneBio, Inc. (IMA) across 2 transactions. The filing covers Common Stock and reflects balanced net activity of $0. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- ImageneBio, Inc.
- Ticker Symbol
- IMA
- CIK
- 0001835579
Insider Information
- Role
- Insider
- Location
- SAN DIEGO, CA
Filing Details
- Filing Date
- Aug 15, 2025
- Transaction Date
- Jul 25, 2025
- Accession Number
- 0001415889-25-022091
- Form Type
- 4
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Jul 25, 2025 | Common Stock | 143,832 | — | Grant/Award | — |
| Jul 25, 2025 | Common Stock | 971,173 | — | Grant/Award | — |
Want live alerts when Wang Jonathan Jian trades again?
Download Insider Trades to track IMA, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)Under the terms of the Agreement and Plan of Merger, dated as of December 23, 2024, by and among, the Issuer, Insight Merger Sub I, a wholly-owned subsidiary of the Issuer ("Merger Sub I"), Insight Merger Sub II, a wholly-owned subsidiary of the Issuer ("Merger Sub II") and Inmagene Biopharmaceuticals ("Legacy Inmagene") (the "Merger Agreement"), on July 25, 2025, Merger Sub I merged with and into Legacy Inmagene (the "First Merger"), with Legacy Inmagene surviving the First Merger as a wholly-owned subsidiary of the Issuer, and immediately after the First Merger, Legacy Inmagene merged with and into Merger Sub II, with Merger Sub II surviving the First Merger as a wholly-owned subsidiary of the Issuer (the "Second Merger" and together with the First Merger, the "Merger"). (continued in the next footnote).
- (F2)Upon the closing of the Merger, each Legacy Inmagene ordinary and preferred share was converted into the right to receive 0.003051 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Ikena Oncology, Inc. ("Ikena") to ImageneBio, Inc.
- (F3)Received in exchange for 47,142,857 Series Seed convertible preferred shares of Legacy Inmagene pursuant to the Merger Agreement.
- (F4)Received in exchange for 318,313,306 ordinary shares of Legacy Inmagene pursuant to the Merger Agreement.
- (F5)Engene Inc.'s sole shareholder is YJH Trust of which Trident Trust Company (HK) Limited serves as trustee. Dr. Wang's spouse and daughter are the sole beneficiaries of YJH Trust. Accordingly, Dr. Wang has an indirect pecuniary interest over the shares of the Issuer held by Engene Inc. Dr. Wang disclaims beneficial ownership of the shares held by Engene Inc. except to the extent of his pecuniary interest therein, if any.